CRISPR-Cas9 Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T-Cell Therapy Post Transplantation

In order to deliver protection against viral pathogens and allow at the same time necessary steroid therapy, scientists generated glucocorticoid-resistant T cells by CRISPR/Cas9-mediated knockout of the glucocorticoid receptor in primary human virus-specific T-cell products.